Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Mylan's EpiPen According to one federal analysis, taxpayers may have overpaid for Mylan’s EpiPen by as much as $1.27 billion over 10 years as a result of its misclassification. (Photo: Shutterstock)

Senators Ron Wyden, D-Oregon, and Chuck Grassley, R-Iowa, have introduced a bill that’s aimed at the methods drug companies use to overcharge taxpayers for Medicaid rebates.

Marlene Satter

Marlene Y. Satter has worked in and written about the financial industry for decades.

More from this author


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.